WK369
WK369 is a novel BCL6 small molecule inhibitor, which exhibits excellent anti-ovarian cancer bioactivity, induces cell cycle arrest and causes apoptosis. WK369 can directly bind to the BCL6-BTB domain and block the interaction between BCL6 and SMRT, leading to the reactivation of p53, ATR and CDKN1A[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; BCL6
Type
Reference compound
Related Pathways
Apoptosis; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/wk369.html
Purity
99.89
Solubility
DMSO : 100 mg/mL (ultrasonic; warming)
Smiles
O=C(C=C1)OC2=C1C=C(NC3=NC(N4C[C@H](C)N[C@H](C)C4)=NC=C3F)C=C2
Molecular Formula
C19H20FN5O2
Molecular Weight
369.39
References & Citations
[1]Wu M, et al. Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer. Int J Biol Sci. 2024 Jan 1;20 (2) :486-501.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
